UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
You may also be interested in...
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup
Sharing costs and risk could help ease UCB’s recent woes with Cimzia, Neupro.